- Home
- ENVB vs APM Comparison
ENVB vs APM Comparison
Compare ENVB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- APM
- Stock Information
- Founded
- ENVB 1994
- APM 2010
- Country
- ENVB United States
- APM United Kingdom
- Employees
- ENVB N/A
- APM N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- APM Health Care
- Exchange
- ENVB Nasdaq
- APM Nasdaq
- Market Cap
- ENVB 4.1M
- APM 4.1M
- IPO Year
- ENVB N/A
- APM 2018
- Fundamental
- Price
- ENVB $0.35
- APM $1.15
- Analyst Decision
- ENVB Strong Buy
- APM
- Analyst Count
- ENVB 1
- APM 0
- Target Price
- ENVB $10.00
- APM N/A
- AVG Volume (30 Days)
- ENVB 1.0M
- APM 7.0M
- Earning Date
- ENVB 11-14-2024
- APM 12-20-2024
- Dividend Yield
- ENVB N/A
- APM N/A
- EPS Growth
- ENVB N/A
- APM N/A
- EPS
- ENVB N/A
- APM 0.00
- Revenue
- ENVB N/A
- APM N/A
- Revenue This Year
- ENVB N/A
- APM $157,729.10
- Revenue Next Year
- ENVB N/A
- APM N/A
- P/E Ratio
- ENVB N/A
- APM $345.64
- Revenue Growth
- ENVB N/A
- APM N/A
- 52 Week Low
- ENVB $0.30
- APM $0.46
- 52 Week High
- ENVB $2.92
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- ENVB 46.61
- APM 47.12
- Support Level
- ENVB $0.35
- APM $1.21
- Resistance Level
- ENVB $0.39
- APM $1.30
- Average True Range (ATR)
- ENVB 0.05
- APM 0.75
- MACD
- ENVB -0.00
- APM -0.06
- Stochastic Oscillator
- ENVB 19.56
- APM 4.58
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.